Received: 10 August 2020
Accepted: 20 April 2021
First Online: 26 April 2021
: The study was approved by the local ethics committee of the Faculty of Medicine of Tottori University (No. 2354). All participants provided written informed consent.
: Not applicable.
: HH received grants and fees from Asahi Kasei Pharma, Chugai Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Pfizer Japan, Taisho Toyama, and Teijin Pharma; grants only from Astellas; and personal fees only from Astellas-Amgen, Eli Lilly Japan, Mochida, MSD, Ono, Takeda, and UCB Japan during the course of the study. HN received grants and personal fees from Chugai Pharmaceutical Co. Ltd., Asahi Kasei Pharma Co., Taisho Toyama Pharmaceutical Co. Ltd., Eisai Co. Ltd., Astellas Pharma Inc., Teijin Pharma Ltd., Takeda Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., and Stryker; grants only from Simizu Hospital, Motomachi Hospital, Misasa Onsen Hospital, Tsuyama Daiichi Hospital, Yowakai, Kaken Pharmaceutical Co. Ltd., Pfizer Japan, MSD, Shionogi & Co. Ltd., Nippon Zoki Pharmaceutical Co. Ltd., AbbVie GK, and Kawashima Corporation; and personal fees only from Eli Lilly Japan, AOSpine, Globus Medical Japan Inc., Hisamitsu Pharmaceutical Co. Inc., Nippon Sigmax Co. Ltd., NuVasive Inc., and Becton, Dickinson and Company not relevant to our submitted work. KM, HM, CT, and MO declare that they have no conflict of interest.